Ipamorelin

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a selective growth hormone releasing peptide (GHRP) and ghrelin receptor (GHS-R) agonist. Developed by Novo Nordisk in the late 1990s, it was designed to stimulate the pituitary gland to release growth hormone in a pulsatile pattern that closely mimics the body's natural GH secretion rhythm. What distinguishes ipamorelin from other GHRPs is its remarkable selectivity for growth hormone release without significantly elevating cortisol, prolactin, or ACTH levels.

The compound works by binding to the growth hormone secretagogue receptor (GHS-R1a) in the pituitary gland, triggering a signaling cascade that results in growth hormone release. Unlike GHRP-6 and GHRP-2, which can also activate cortisol and prolactin pathways, ipamorelin demonstrates a high degree of selectivity. This means it may stimulate growth hormone release while producing fewer unwanted hormonal side effects, making it one of the most well-tolerated GHRPs studied to date.

While ipamorelin has been the subject of multiple published research studies, it is not currently FDA-approved for any clinical indication. It remains classified as a research peptide. However, it has gained significant attention in clinical research and peptide therapy circles due to its favorable selectivity profile, well-characterized pharmacology, and relatively mild side effect profile compared to other growth hormone secretagogues.

Clinical Research & Evidence

Ipamorelin has been studied in several published research papers that characterize its pharmacological properties and biological effects. The foundational study by Raun et al. (1998) published in the European Journal of Endocrinology demonstrated that ipamorelin selectively released growth hormone in a dose-dependent manner without significantly affecting ACTH, cortisol, prolactin, FSH, LH, or TSH levels in both in vitro and in vivo models. This selectivity profile was identified as a key differentiator from other GHRPs.

Gobburu et al. (1999) published a pharmacokinetic/pharmacodynamic modeling study characterizing ipamorelin's GH-stimulating effects. The research demonstrated a clear dose-response relationship and established the compound's pharmacokinetic parameters, including its approximately 2-hour half-life and rapid onset of action. The study provided important data on the temporal relationship between ipamorelin administration and growth hormone release peaks.

Research by Svensson et al. (2000) further explored ipamorelin's effects on growth hormone secretion in human subjects, confirming the dose-dependent GH release previously observed in animal studies. The study noted that ipamorelin produced meaningful increases in plasma GH concentrations without clinically significant changes in other pituitary hormones, reinforcing the compound's selectivity advantage. Additional research has explored potential applications in post-surgical recovery, where growth hormone support may aid healing processes.

While the existing research base is promising, it is important to note that ipamorelin has not completed the full regulatory approval process. Large-scale Phase III clinical trials for specific therapeutic indications have not been published. The current evidence supports the compound's pharmacological profile and mechanism of action but does not constitute the level of evidence required for FDA approval. Ongoing research continues to explore its potential therapeutic applications.

Potential Benefits

• Pulsatile GH release: Research suggests ipamorelin triggers growth hormone release in a pattern that mimics the body's natural pulsatile rhythm, which may be more physiologically appropriate than continuous GH elevation.
• Selective hormone stimulation: Studies indicate that ipamorelin does not significantly increase cortisol, prolactin, or ACTH, making it one of the cleanest GHRPs in terms of hormonal side effects.
• Improved sleep quality: Growth hormone is naturally released in larger pulses during deep sleep. Research suggests that GH secretagogues like ipamorelin may support deeper, more restorative sleep patterns.
• Enhanced recovery: Elevated growth hormone levels are associated with improved tissue repair, muscle recovery, and wound healing. Ipamorelin may support these processes through GH-mediated pathways.
• Body composition support: Studies suggest that GH release may promote fat metabolism (particularly visceral fat) while supporting lean muscle mass preservation.
• Anti-aging potential: Growth hormone levels naturally decline with age (somatopause). Research suggests that restoring more youthful GH pulsatility may support skin quality, energy levels, and overall vitality.
• Bone density support: Growth hormone plays a role in bone metabolism and turnover. GH-stimulating compounds may support bone mineral density maintenance.
• Well-tolerated profile: Compared to other GHRPs, ipamorelin is associated with fewer side effects, particularly the absence of significant hunger stimulation (unlike GHRP-6) and cortisol elevation.

Dosing Protocol

The most commonly referenced protocol involves 200-300 mcg administered subcutaneously 2-3 times per day. The timing of injections is considered important: administering on an empty stomach (at least 30 minutes before eating or 2 hours after a meal) may optimize GH release, as elevated blood sugar and insulin can blunt the GH response. Many users favor a bedtime dose to amplify the natural nocturnal GH pulse. A morning dose upon waking and a post-workout dose are also common timing strategies.

Starting at a lower dose (100-200 mcg per injection) and gradually increasing allows the body to adjust and helps identify individual tolerance. Cycling is generally recommended (8-12 weeks on, 4 weeks off) to prevent receptor desensitization and maintain endogenous GH axis function. Always consult a qualified healthcare provider for personalized dosing guidance.

Reconstitution Guide

Ipamorelin is supplied as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water (BAC water) before use. The reconstitution process is straightforward but requires careful aseptic technique to maintain sterility.

Step-by-step instructions: (1) Wipe the vial stopper and BAC water vial with alcohol swabs. (2) Draw the desired volume of BAC water into an insulin syringe. (3) Inject the water slowly along the inside wall of the vial, allowing it to drip gently onto the lyophilized powder. Do not spray directly onto the cake or shake vigorously. (4) Gently swirl the vial until the powder is completely dissolved. The solution should be clear and colorless. (5) Store the reconstituted vial in the refrigerator at 2-8 degrees Celsius and use within 30 days. (6) When drawing a dose, always use a clean, sterile syringe and wipe the vial stopper with alcohol before each use.

Half-Life & Pharmacokinetics

Ipamorelin has an elimination half-life of approximately 2 hours following subcutaneous administration. After injection, the peptide is rapidly absorbed from the subcutaneous tissue into systemic circulation, reaching peak plasma concentrations within approximately 15-30 minutes. The growth hormone release stimulated by ipamorelin follows a pulsatile pattern, with peak GH levels occurring approximately 30-60 minutes after administration and returning toward baseline within 2-3 hours.

The compound is metabolized through proteolytic degradation, as is typical for peptide-based compounds. Its relatively short half-life supports the rationale for multiple daily dosing to maintain optimal GH stimulation throughout the day. The pharmacodynamic effects (the GH release response) may persist somewhat longer than the pharmacokinetic half-life would suggest, as the downstream effects of released growth hormone continue through IGF-1 mediation for hours after the ipamorelin itself has been cleared. This pulsatile GH release pattern is considered advantageous because it more closely resembles natural endogenous GH secretion compared to the constant elevation produced by exogenous GH administration.

Administration & Injection Sites

Ipamorelin is administered via subcutaneous injection using an insulin syringe (typically 29-31 gauge, 0.5-1 mL). The injection is quick, relatively painless due to the small needle gauge, and can be self-administered after proper training. Because ipamorelin works systemically by stimulating the pituitary gland, the specific injection site does not affect efficacy.

For optimal growth hormone release, administer ipamorelin on an empty stomach. Fats and carbohydrates can blunt the GH response, so waiting at least 30 minutes before eating after injection is commonly recommended. Bedtime dosing is particularly popular as it aligns with the body's natural nocturnal GH pulse and avoids interference from food intake.

• Abdomen: Preferred site for most users. Inject 1-2 inches from the navel, rotating within the abdominal area.
• Thigh: Upper outer thigh provides a good alternative site with consistent subcutaneous fat coverage.

Pinch a fold of skin, insert the needle at a 45-90 degree angle, and inject slowly. After injection, release the skin fold and apply gentle pressure with a gauze pad. Rotate injection sites to prevent localized tissue irritation. Dispose of used needles and syringes in an appropriate sharps container.

Side Effects & Safety

Ipamorelin is generally considered one of the better-tolerated growth hormone secretagogues, with a mild side effect profile compared to other GHRPs. Its selectivity for GH release without cortisol or prolactin elevation contributes to its favorable safety characteristics.

Common Side Effects

• Increased hunger (common): Mild appetite stimulation due to ghrelin receptor activation. Less pronounced than with GHRP-6 but still noticeable for some users.
• Injection site reactions (common): Mild redness, itching, or soreness at the injection site. Typically resolves within hours.
• Water retention (common): Mild fluid retention, particularly in the initial weeks, related to GH-mediated effects. Usually subsides as the body adjusts.

Uncommon Side Effects

• Headache (uncommon): Occasional mild headache or lightheadedness, typically transient and dose-related.
• Tingling or numbness (uncommon): Paresthesias in the hands or feet, related to GH-mediated fluid shifts. Usually mild and temporary.
• Joint stiffness (uncommon): Mild joint discomfort may occur with elevated GH levels, particularly during the first few weeks.

Rare Side Effects

• Transient blood sugar changes (rare): GH can have anti-insulin effects; significant glucose changes are uncommon with ipamorelin alone but possible in susceptible individuals.

Stacking & Interactions

Ipamorelin is frequently combined with other peptides, particularly CJC-1295, to enhance and prolong the growth hormone response. Understanding the interactions between these compounds is important for optimizing results and minimizing risks.

The CJC-1295/Ipamorelin combination (often called "CJC/Ipa") is one of the most widely referenced peptide stacks. The rationale is that CJC-1295 acts as a GHRH analog (stimulating the release pathway) while ipamorelin acts as a GHRP (amplifying the signal), resulting in synergistic GH release that is greater than either compound alone. Many providers offer this combination as a pre-mixed blend.

Storage & Handling

Lyophilized (unreconstituted) powder: Ipamorelin in its freeze-dried form is relatively stable and can be stored at room temperature (below 25 degrees Celsius) for several months, or refrigerated (2-8 degrees Celsius) for 1-2 years. For maximum shelf life, store at -20 degrees Celsius (freezer). Protect from light, moisture, and temperature fluctuations. The lyophilized form is significantly more stable than the reconstituted solution.

Reconstituted solution: Once reconstituted with bacteriostatic water, ipamorelin must be refrigerated at 2-8 degrees Celsius and used within 30 days. The bacteriostatic preservative in BAC water (0.9% benzyl alcohol) helps prevent microbial growth during this period. Do not freeze the reconstituted solution. If reconstituted with sterile water (no preservative), use within 48-72 hours.

Travel tips: Transport lyophilized powder at ambient temperature for short trips (it is stable at room temperature for weeks to months). For reconstituted solution, use an insulated pouch with an ice pack to maintain cold chain. Do not leave reconstituted ipamorelin in a hot car or exposed to sunlight.

Signs of degradation: The reconstituted solution should be clear and colorless. Discard if it becomes cloudy, develops particles, changes color, or has an unusual odor. Also discard if the storage conditions have been compromised or the expiration period has elapsed.

Legal & Regulatory Status

Ipamorelin is not FDA-approved for any clinical indication in the United States. It is classified as a research peptide and is typically sold under designations such as "for research use only." It is not a controlled substance under the Controlled Substances Act, but its use in humans is not sanctioned by the FDA.

The compound is prohibited by the World Anti-Doping Agency (WADA) under the S2 category of peptide hormones, growth factors, related substances, and mimetics. Athletes subject to anti-doping testing should be aware that use of ipamorelin or any growth hormone secretagogue constitutes a doping violation. It is similarly banned by virtually all professional and amateur sports organizations.

In some countries, ipamorelin and other peptides may be available through compounding pharmacies with a valid prescription from a licensed healthcare provider. Regulatory frameworks for peptide therapy vary significantly by jurisdiction. In the United States, the FDA has taken regulatory action regarding certain peptide products, and the availability of specific peptides through compounding pharmacies may change over time. Users should stay informed about current regulations in their area.

Recommended Bloodwork & Monitoring

Regular bloodwork is recommended to assess the effects of ipamorelin on growth hormone levels and to monitor for potential metabolic changes. The following panels should be discussed with your healthcare provider.

Before Starting

• IGF-1 serum level: The most practical marker for growth hormone status; establishes baseline for tracking response
• Growth hormone level (fasting): Optional baseline, though IGF-1 is generally more reliable due to GH's pulsatile nature
• Fasting blood glucose and HbA1c: Baseline glucose metabolism assessment, as GH has anti-insulin effects
• Fasting insulin level: Evaluate insulin sensitivity
• Complete metabolic panel (CMP): Liver function, kidney function, and electrolytes
• Complete blood count (CBC): Baseline hematologic values
• Thyroid panel (TSH, Free T3, Free T4): GH can influence thyroid hormone conversion

During Use (every 6-8 weeks)

• IGF-1 serum level: The primary marker to confirm the compound is stimulating GH release; optimal range is typically upper-normal for age
• Fasting blood glucose: Monitor for any glucose metabolism changes related to GH elevation
• HbA1c: Assess longer-term glucose trends, especially after 3+ months of use
• Liver function tests: Periodic monitoring of hepatic health
• Symptom tracking: Document sleep quality, energy levels, recovery, body composition changes, and any side effects

Frequently Asked Questions

Published Research

• Gobburu et al., 1999 - PK/PD modeling PMID: 10342805
• Svensson et al., 2000 - GH secretion study PMID: 10999822
• Raun et al., 1998 - Selectivity of ipamorelin PMID: 9849822

Related Compounds